tirzepatide lawsuit Zepbound [2026] Weight loss drug lawsuit: Mounjaro

NO., number

DiabetesRisk Reduction Trial (3 years) In overweight/pre-diabetic adults, tirzepatide reduced progression to type 2 diabetes by 94%, with ~22.9% average weight loss at highest dose

Retatrutide 20mg activates all three: GLP-1, GIP, and the glucagon receptor simultaneously

the website doesn't have anywhere to input your weight or shots

"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA." The New England Journal of Medicine, 2023

These injections assist in breaking down fat, supporting red blood cell production, and improving oxygen flow for sustained energy